Evaxion Biotech A/S (EVAX)
NASDAQ: EVAX
· Real-Time Price · USD
3.23
0.35 (12.15%)
At close: Aug 18, 2025, 3:59 PM
3.15
-2.41%
Pre-market: Aug 19, 2025, 04:13 AM EDT
12.15% (1D)
| Bid | 3.06 |
| Market Cap | 20.39M |
| Revenue (ttm) | 3.3M |
| Net Income (ttm) | -13.34M |
| EPS (ttm) | -12 |
| PE Ratio (ttm) | -0.27 |
| Forward PE | -1.55 |
| Analyst | Buy |
| Ask | 3.15 |
| Volume | 353,288 |
| Avg. Volume (20D) | 115,370 |
| Open | 2.95 |
| Previous Close | 2.88 |
| Day's Range | 2.90 - 3.23 |
| 52-Week Range | 1.20 - 17.75 |
| Beta | 0.14 |
About EVAX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol EVAX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for EVAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 days ago
-5.92%
Evaxion shares are trading lower after the company...
Unlock content with
Pro Subscription
2 months ago
+25.53%
Evaxion shares are trading higher after the company reported better-than-expected Q1 GAAP EPS results.
2 months ago · seekingalpha.com
Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call TranscriptEvaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call May 27, 2025 8:30 PM ET Company Participants Christian Kanstrup - CEO Birgitte Rono - Chief Scientific Officer Thomas Schmidt - CFO Conferen...
2 months ago · seekingalpha.com
Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily ...